To access this page on Cerebrolysin® please confirm
that you are a healthcare professional.
NO, I AM NOT A HEALTHCARE PROFESSIONAL
20.01.2026

CREGS Launch - Study Insights and First Expert Reactions

Watch the video to gain deeper insights into the CREGS study and its clinical relevance!
Read more
08.01.2026

WSC 2025, Barcelona - EVER Symposium

Breakthroughs in AIS Therapy: Recent trial results in evidence-based cerebroprotection
Read more
17.12.2025

Key Insights from the IMMM 2025

Read the report now!
Read more
20.11.2025

Austrian Vietnamese Advancement Neurorehabilitation Treatment

Deeper insights with the Access to Care Questionnaire
Read more
Go to Archive

Congresses

11th European Stroke Organisation Conference

Helsinki, Finland
21 - 23 May 2025
GO TO EVENT

17th World Stroke Congress

Barcelona, Spain
22 - 25 October 2025
GO TO EVENT

Notice to U.S. Visitors

Please be advised that Cerebrolysin is not registered with the U.S. Food and Drug Administration (FDA) and is not approved for sale or distribution in the United States.

Cerebrolysin is a prescription medication for use under the supervision of an authorized health care professional. For any medical inquiries, please consult with a healthcare professional.